Retrophin and its former CEO “Pharma Bro” Martin Shkreli are facing claims by a rival drug company for monopolizing the market for Thiola, the only drug approved to treat a genetic disease that results in recurring kidney stones.
Spring Pharmaceuticals filed the lawsuit on October 24 in the US District Court for the Eastern District of Pennsylvania seeking treble damages and a permanent injunction against Retrophin, Shkreli, Mission Pharmacal, and Alamo Pharma Services.
Full Content: Law 360
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
